Literature DB >> 7186901

Prevalence of antibodies to Legionella pneumophila in animal populations.

M T Collins, S N Cho, J S Reif.   

Abstract

We examined more than 2,800 human and animal sera for antibodies to four serogroups of Legionella pneumophila by using the microagglutination test. Antibody titers of greater than or equal to 1:64 were considered positive. The occurrence of positive equine sera (31.4%) was significantly higher than the occurrence of positive sera in cattle (5.1%), swine (2.9%), sheep (1.9%), dogs (1.9%), goats (0.5%), wildlife (0%), and humans (0.4%). The highest titer measured in horses was 1:512. The occurrence of positive sera in horses was related directly to age. In horses less than or equal to 1, 2 to 3, 4 to 7, 8 to 12, and greater than or equal to 13 years old, the percentages of positive sera were 0, 10.1, 30.3, 44.9 and 58.1%, respectively. When we compared age-specific serogroup-specific rates in horses from Colorado and Pennsylvania, we found differences. With horses 8 to 12 and greater than or equal to 13 years old, there was a significantly higher (P less than 0.05) occurrence of sera that reacted to serogroups II and III in horses from Pennsylvania. Of 242 positive sera, 43.8% reacted to a single serogroup (serogroup III or I most commonly), and 56.2% reacted to multiple serogroups (serogroups II and III or serogroups I, II, and III most commonly). A high percentage of seropositive horses suggested that horses are commonly infected with L. pneumophila or related organisms, and the age-specific rates of occurrence indicated that infection was related directly to duration of exposure. A definitive demonstration of equine infection will depend on isolation of the agent and repetition of this serological study with antigens obtained from organisms isolated from horses.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7186901      PMCID: PMC272037          DOI: 10.1128/jcm.15.1.130-136.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  An outbreak in 1965 of severe respiratory illness caused by the Legionnaires' disease bacterium.

Authors:  S B Thacker; J V Bennett; T F Tsai; D W Fraser; J E McDade; C C Shepard; K H Williams; W H Stuart; H B Dull; T C Eickhoff
Journal:  J Infect Dis       Date:  1978-10       Impact factor: 5.226

2.  Sporadic community-acquired Legionnaires' disease in the United States. A case-control study.

Authors:  G Storch; W B Baine; D W Fraser; C V Broome; H W Clegg; M L Cohen; S A Goings; B D Politi; W A Terranova; T F Tsai; B D Plikaytis; C C Shepard; J V Bennett
Journal:  Ann Intern Med       Date:  1979-04       Impact factor: 25.391

3.  Immunochemical, serologic, and immunologic properties of major antigens isolated from the Legionnaires' disease bacterium. Observations bearing on the feasibility of a vaccine.

Authors:  K H Wong; W O Schalla; R J Arko; J C Bullard; J C Feeley
Journal:  Ann Intern Med       Date:  1979-04       Impact factor: 25.391

4.  Pontiac fever. An epidemic of unknown etiology in a health department: I. Clinical and epidemiologic aspects.

Authors:  T H Glick; M B Gregg; B Berman; G Mallison; W W Rhodes; I Kassanoff
Journal:  Am J Epidemiol       Date:  1978-02       Impact factor: 4.897

5.  Ecological distribution of Legionella pneumophila.

Authors:  C B Fliermans; W B Cherry; L H Orrison; S J Smith; D L Tison; D H Pope
Journal:  Appl Environ Microbiol       Date:  1981-01       Impact factor: 4.792

6.  Detection of antibodies to legionnaires disease organism by microagglutination and micro-enzyme-linked immunosorbent assay tests.

Authors:  C E Farshy; G C Klein; J C Feeley
Journal:  J Clin Microbiol       Date:  1978-04       Impact factor: 5.948

7.  Legionnaires' disease: description of an epidemic of pneumonia.

Authors:  D W Fraser; T R Tsai; W Orenstein; W E Parkin; H J Beecham; R G Sharrar; J Harris; G F Mallison; S M Martin; J E McDade; C C Shepard; P S Brachman
Journal:  N Engl J Med       Date:  1977-12-01       Impact factor: 91.245

8.  Prevalence of antibody to the Legionnaires' disease bacterium in hospital employees.

Authors:  L Saravolatz; L Arking; B Wentworth; E Quinn
Journal:  Ann Intern Med       Date:  1979-04       Impact factor: 25.391

9.  A major focus of Legionnaires' disease in Bloomington, Indiana.

Authors:  B D Politi; D W Fraser; G F Mallison; J V Mohatt; G K Morris; C M Patton; J C Feeley; R D Telle; J V Bennett
Journal:  Ann Intern Med       Date:  1979-04       Impact factor: 25.391

10.  Legionnaires' disease in a prepaid medical-care group in Seattle 1963--75.

Authors:  H M Foy; C V Broome; P S Hayes; I Allan; M K Cooney; R Tobe
Journal:  Lancet       Date:  1979-04-07       Impact factor: 79.321

View more
  5 in total

1.  Epidemiological and environmental investigations of Legionella pneumophila infection in cattle and case report of fatal pneumonia in a calf.

Authors:  M Fabbi; M C Pastoris; E Scanziani; S Magnino; L Di Matteo
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

2.  A survey of domestic animals to detect serological responses against Legionella spp. by indirect fluorescent antibody.

Authors:  T C Barth; E D Renner; D A Gabrielson
Journal:  Can J Comp Med       Date:  1983-07

3.  Comparison of microagglutination with the indirect immunofluorescence assay for the diagnosis of infection with Legionella pneumophila serogroup 1.

Authors:  N Bornstein; J Fleurette
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

4.  Agglutinating antibody titers to members of the family Legionellaceae in cystic fibrosis patients as a result of cross-reacting antibodies to Pseudomonas aeruginosa.

Authors:  M T Collins; J McDonald; N Høiby; O Aalund
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

5.  Review Global seroprevalence of legionellosis - a systematic review and meta-analysis.

Authors:  Frances F Graham; Simon Hales; Paul S White; Michael G Baker
Journal:  Sci Rep       Date:  2020-04-30       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.